Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas-Reference-Cited by-同舟云学术

Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas

Published:2015-01-27 Issue:1 Volume:6 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Castro-Vega Luis Jaime,Letouzé Eric,Burnichon Nelly,Buffet Alexandre,Disderot Pierre-Hélie,Khalifa Emmanuel,Loriot Céline,Elarouci Nabila,Morin Aurélie,Menara Mélanie,Lepoutre-Lussey Charlotte,Badoual Cécile,Sibony Mathilde,Dousset Bertrand,Libé Rossella,Zinzindohoue Franck,Plouin Pierre François,Bertherat Jérôme,Amar Laurence,de Reyniès Aurélien,Favier Judith,Gimenez-Roqueplo Anne-Paule

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry

Link

http://www.nature.com/articles/ncomms7044.pdf

Reference62 articles.

1. Dahia, P. L. Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity. Nat. Rev. Cancer. 14, 108–119 (2014).

2. Gimenez-Roqueplo, A. P. et al. Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res. 63, 5615–5621 (2003).

3. Amar, L. et al. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J. Clin. Endocrinol. Metab. 92, 3822–3828 (2007).

4. Castro-Vega, L. J. et al. Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas. Hum. Mol. Genet. 23, 2440–2446 (2014).

5. Burnichon, N. et al. Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma. Hum. Mol. Genet. 21, 5397–5405 (2012).

Cited by 153 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metabolomics and proteomics in pheochromocytoma/paraganglioma: translating biochemistry and biology to bedside;Best Practice & Research Clinical Endocrinology & Metabolism;2024-09

2. MAML3-fusions modulate vascular and immune tumour microenvironment and confer high metastatic risk in pheochromocytoma and paraganglioma;Best Practice & Research Clinical Endocrinology & Metabolism;2024-08

3. Personalized management for phaeochromocytomas and paragangliomas in Latin America: A genetic perspective;Best Practice & Research Clinical Endocrinology & Metabolism;2024-08

4. Identification of Predictors of Metastatic Potential in Paragangliomas to Develop a Prognostic Score (PSPGL);Journal of the Endocrine Society;2024-05-07

5. Prediction model for pheochromocytoma/paraganglioma using nCounter assay;Journal of Surgical Oncology;2024-04-18